Gelonghui Announcement Highlights (Hong Kong Stocks) | Leapmotor (09863.HK) third-quarter revenue increased by 74.3% year-on-year to 9.86 billion yuan, expected to exceed the annual gross margin target.

【Today's Focus】Leapmotor (09863.HK) third-quarter revenue increased by 74.3% year-on-year to 9.86 billion yuan. Expected to exceed the annual gross margin target Leapmotor (09863.HK) announced that in the third quarter of 2024, the company's revenue was 9.86 billion yuan, an 83.9% increase from the second quarter, a 74.3% increase from 2023, mainly due to the significant increase in product delivery volume and optimization of product sales structure. The gross margin in the third quarter of 2024 was 8.1%, a significant improvement from 2.8% in the second quarter of 2024.

Gelonghui FinanceNov 11 09:47 ET

Express News | Biocytogen Announces Ideaya’s Nomination of Development Candidate Ide034, a Potential First-in-Class B7H3/Ptk7 Topo-I-Payload Bispecific ADC and Option Exercise

ReutersNov 11 06:00 ET

BeiGene-Bei (02315.HK): IDEAYA nominates B7H3/PTK7 dual-specific ADC with first-in-class potential as a development candidate drug and exercises the right of selection in parallel.

Grallhu November 11th | Beiou Sai Tu-B (02315.HK) announced that IDEAYA Biosciences, Inc. (nasdaq: IDYA) (IDEAYA), a precision medical company dedicated to the discovery and development of targeted therapeutic drugs for tumors, has exercised its option to obtain the global exclusive license for B7H3/PTK7 topoisomerase inhibitor payload dual-specific antibody-drug conjugate (BsADC) BCG034 (IDE034) with similar first-in-class potential as Beiou Sai Tu, and nominated the project as a development candidate drug.

Gelonghui FinanceNov 11 05:35 ET

BIOCYTOGEN-B: 2024 Interim Report

HKEXSep 25 04:45 ET · Announcements

Baostar Technologies Limited (02315.HK) received a shareholding increase of 0.7 million shares from Veken Trading (Hong Kong) Limited.

According to the latest equity disclosure information from the Hong Kong Stock Exchange, on September 11, 2024, Vico (Hong Kong) Economic and Trade Limited purchased 0.7 million shares of Baoshitubo-B (02315.HK) on the exchange at an average price of HK $5.85 per share, with a total investment of approximately HK $4.095 million. After the increase, the latest holding of Vico (Hong Kong) Economic and Trade Limited is 7.10258 million shares, and the shareholding ratio has increased from 5.78% to 6.41%.

Gelonghui FinanceSep 12 18:47 ET

Picoocart-B (2315.HK): Continuous revenue growth, significant narrowing of losses, positive operation cash flow, successful landing imminent.

In the past two or three years, innovation, going global, and profitability have become a consensus among entrepreneurs and investors in the domestic biomedical industry after the roller coaster-like changes. From the perspective of the capital markets, the performance of the innovative drug sector in the Hong Kong stock market in recent years has been disappointing, and the market's valuation attitude towards this sector has changed from overvaluation bubble to irrational undervaluation. With the continuous adjustment of sector valuation, it is currently at a historical low, providing a good opportunity for value-seeking investors. At this point in time, overseas innovative drug research and development is still thriving, and the domestic market is also gradually receiving support from the latest policies and market demand.

Gelonghui FinanceAug 28 20:41 ET